Green Apple/shutterstock.com
Healthcare provider Zydus Cadila has signed a sub-licensing agreement with the Medicines Patent Pool (MPP) centring on the generic production of Daklinza (daclatasvir).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Zydus Cadila, MPP, Bristol-Myers Squibb, Daklinza
